22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets.
22nd Century Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.90|
|52 Week High||US$0.68|
|52 Week Low||US$6.07|
|1 Month Change||-4.61%|
|3 Month Change||-12.91%|
|1 Year Change||223.30%|
|3 Year Change||5.84%|
|5 Year Change||110.15%|
|Change since IPO||123.08%|
Recent News & Updates
22nd Century: Third Plant-Based Franchise And Record Q2 Revenues
Hops is an essential ingredient for brewing beer and has similar properties to cannabis. XXII announced Monday a new subsidiary in the Netherlands where they will develop partnerships for selling strain specific hops. They will use their partnerships with CannaMetrix and KeyGene to innovate hops genetics. The company reported record revenues for Q2 and expects growth over Q3/Q4 from their hemp/cannabis franchise segment. I rate their stock as bullish and recommend a long-hold position.
|XXII||US Tobacco||US Market|
Return vs Industry: XXII exceeded the US Tobacco industry which returned 23.4% over the past year.
Return vs Market: XXII exceeded the US Market which returned 30% over the past year.
Stable Share Price: XXII is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: XXII's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications.
22nd Century Group Fundamentals Summary
|XXII fundamental statistics|
Is XXII overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|XXII income statement (TTM)|
|Cost of Revenue||US$27.61m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.12|
|Net Profit Margin||-66.55%|
How did XXII perform over the long term?See historical performance and comparison
Is 22nd Century Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate XXII's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate XXII's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: XXII is unprofitable, so we can't compare its PE Ratio to the Global Tobacco industry average.
PE vs Market: XXII is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate XXII's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: XXII is good value based on its PB Ratio (5.4x) compared to the US Tobacco industry average (6.1x).
How is 22nd Century Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XXII is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XXII is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XXII is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XXII's revenue (65.5% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: XXII's revenue (65.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XXII's Return on Equity is forecast to be high in 3 years time
How has 22nd Century Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XXII is currently unprofitable.
Growing Profit Margin: XXII is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XXII is unprofitable, and losses have increased over the past 5 years at a rate of 19.2% per year.
Accelerating Growth: Unable to compare XXII's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XXII is unprofitable, making it difficult to compare its past year earnings growth to the Tobacco industry (10.3%).
Return on Equity
High ROE: XXII has a negative Return on Equity (-22.7%), as it is currently unprofitable.
How is 22nd Century Group's financial position?
Financial Position Analysis
Short Term Liabilities: XXII's short term assets ($70.7M) exceed its short term liabilities ($9.2M).
Long Term Liabilities: XXII's short term assets ($70.7M) exceed its long term liabilities ($553.0K).
Debt to Equity History and Analysis
Debt Level: XXII's debt to equity ratio (3%) is considered satisfactory.
Reducing Debt: XXII's debt to equity ratio has reduced from 4.5% to 3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XXII has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: XXII has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 11.9% each year.
What is 22nd Century Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XXII's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XXII's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XXII's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XXII's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XXII's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jim Mish (57 yo)
Mr. James A. Mish, also known as Jim, serves as Chief Executive Officer at 22nd Century Group, Inc. since June 22, 2020. He has extensive global executive leadership experience in science-driven organizati...
CEO Compensation Analysis
Compensation vs Market: Jim's total compensation ($USD1.26M) is about average for companies of similar size in the US market ($USD1.70M).
Compensation vs Earnings: Insufficient data to compare Jim's compensation with company performance.
Experienced Management: XXII's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Experienced Board: XXII's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: XXII insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.2%.
22nd Century Group, Inc.'s employee growth, exchange listings and data sources
- Name: 22nd Century Group, Inc.
- Ticker: XXII
- Exchange: NasdaqCM
- Founded: 1998
- Industry: Tobacco
- Sector: Food, Beverage & Tobacco
- Market Cap: US$471.933m
- Shares outstanding: 162.74m
- Website: https://www.xxiicentury.com
Number of Employees
- 22nd Century Group, Inc.
- 500 Seneca Street
- Suite 507
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 23:45|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.